Princeton Junction, NJ, United States of America

Rajeev S Bhide

This inventor holds 34 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Kinase Inhibitors. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2000-2023.

USPTO Granted Patents = 34 (Patent Applications = 5)

% Patents Active = 94.1

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 4.8

ph-index = 11

Forward Citations = 380(Granted Patents)

Location History:

Langhorne, PA (US) (2000 - 2007)
Princeton Jct, NJ (US) (2006 - 2009)
Bengaluru, IN (2018 - 2019)
Princeton Junction, NJ (US) (2005 - 2023)

Company Filing History:

34 out of 3,735

Bristol-Myers Squibb Compnay

patents

Years Active: 2000-2023

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Pyrrolotriazine Compounds

Heterocyclic Derivatives

Farnesyl Protein Transferase

Spiro-Fused Cyclic Ureas

Bicyclic Heterocycles

Azaindole Compounds

Triazolyl-Substituted

ROCK Inhibitors

ROMK Channel Inhibitors

Heteroaryl Compounds

Cyclic Ureas

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE49700 - Substituted nitrogen containing compounds (2023-10-17),

2. 10787450 - Spiro-fused cyclic ureas as inhibitors of rock (2020-09-29),

3. 10723723 - Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors (2020-07-28),

4. 10654860 - Tricyclic rho kinase inhibitors (2020-05-19),

5. 10544133 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2020-01-28),

6. 10501449 - Substituted nitrogen containing compounds (2019-12-10),

7. 10214537 - Bicyclic heteroaryl amine compounds (2019-02-26),

8. 10123993 - Cyclic ureas as inhibitors of rock (2018-11-13),

9. 10023576 - Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors (2018-07-17),

10. 10023562 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2018-07-17),

11. 9657009 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2017-05-23),

12. 9546153 - Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators (2017-01-17),

13. 8987311 - Triazolyl-substituted pyridyl compounds useful as kinase inhibitors (2015-03-24),

14. 8148361 - Kinase inhibitors (2012-04-03),

15. 7820814 - Inhibitors of kinases (2010-10-26),

Title: **Innovative Contributions of Rajeev S. Bhide in Cardiovascular Research**

Introduction

Rajeev S. Bhide is a prominent inventor based in Princeton Junction, NJ. With an impressive portfolio of 34 patents, he has made significant advancements in the field of pharmaceutical research, particularly focusing on cardiovascular diseases.

Latest Patents

Among Rajeev's latest innovations is a patent on substituted nitrogen-containing compounds, which includes compounds of Formula (I) and their respective salts. These compounds are designed as inhibitors of the ROMK potassium channels, with potential applications in treating cardiovascular diseases. Additionally, he has developed spiro-fused cyclic ureas that selectively inhibit ROCK (Rho-associated protein kinase). This invention includes pharmaceutical compositions and methods for utilizing these compounds in treating various disorders, including oncologic, neuropathologic, autoimmune, fibrotic, and inflammatory conditions.

Career Highlights

Rajeev S. Bhide works at Bristol-Myers Squibb, a leading biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines. His contributions significantly enhance the company's capabilities in addressing critical health challenges.

Collaborations

Throughout his career, Rajeev has collaborated with talented colleagues such as Ligang Qian and John T. Hunt. These collaborations have undoubtedly enriched the research process and led to the development of effective therapeutic solutions.

Conclusion

In summary, Rajeev S. Bhide’s innovative work and numerous patents showcase his dedication to advancing medical science, specifically in the realm of cardiovascular health. His contributions not only reflect his expertise as an inventor but also illustrate the impactful collaborations in the pharmaceutical industry.